The APRI and ALBI scores are commonly used in clinical routine to assess the severity of illness for patients suffering from hepatical tumors and to predict postoperative liver dysfunction after resection. Combining these scores, the APRI+ALBI score provides even better performance of assessment and prediction regarding 30-day-mortality after surgery. TELLAPRIALBI allows you to – enter relevant lab parameters (platelet count, AST, albumin and bilirubin levels) – automatically compute APRI, ALBI and APRI+ALBI scores for comparative review – select from a variety of tumor types together with the respective extent of resection and – view clinical interpretation plots regarding 30-day-mortality post operation highlighting the risk class indicated by the APRI+ALBI score. The app is intended for educational use by medical professionals and to allow review of the APRI+ALBI score and its predictive quality. All information entered into the app and computed by it is processed exclusively within the app on the users device and no information is stored, transmitted or shared by the app. TELLAPRIALBI was developed jointly by the Translational Experimental Liver Laboratory at the Medical University of Vienna (TELLVIENNA) and 37binary UG (haftungsbeschränkt). It is based on a joint research paper which is currently in print at BMJ Open. The app is published by and the service is provided by 37binary UG (haftungsbeschränkt).
TherEx Anywhere
为您提供TherEx A应用描述查询,TherEx A应用截图，TherEx A应用包信息以及TherEx A版本记录查询等服务。